Recent advances in nonalcoholic fatty liver disease metabolomics

被引：54

作者：

Kim, Hwi Young ^{[1
]}

机构：

[1] Ewha Womans Univ, Dept Internal Med, Coll Med, 1071 Anyangcheon Ro, Seoul 07985, South Korea

来源：

CLINICAL AND MOLECULAR HEPATOLOGY | 2021年 / 27卷 / 04期

基金：

新加坡国家研究基金会;

关键词：

Lipids; Bile acids and salts; Amino acids; Fatty liver; Phenotype; INSULIN-RESISTANCE; SYSTEMS BIOLOGY; FIBROSIS STAGE; STEATOHEPATITIS; NAFLD; MORTALITY; OBESITY; NASH;

D O I：

10.3350/cmh.2021.0127

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

The clinical phenotypes of nonalcoholic fatty liver disease (NAFLD) encompass from simple steatosis to nonalcoholic steatohepatitis (NASH) with varying degrees of fibrosis or cirrhosis. Liver biopsy has been the standard to diagnose NASH. However, there has been strong need for precise and accurate noninvasive tests because of invasiveness and sampling variability of biopsy. Metabolomics has drawn attention as a promising diagnostic methodology in the field of NAFLD, particularly to unravel metabolic alterations which plays relevant roles in the progression of NASH. There have been numerous metabolomics researches to find new biomarker of NASH in the last decade, fueled by the recent advances in the metabolomics methodology. This review briefly covers recent research advances on the lipidomics, amino acids and bile acid metabolomics regarding continuing attempts to discover relevant biomarkers for NASH. (Clin Mol Hepatol 2021;27:553-559)

引用

页码：553 / 559

页数：7

共 34 条

[1] Obesity-Dependent Metabolic Signatures Associated with Nonalcoholic Fatty Liver Disease Progression [J].

Barr, J. ;

Caballeria, J. ;

Martinez-Arranz, I. ;

Dominguez-Diez, A. ;

Alonso, C. ;

Muntane, J. ;

Perez-Cormenzana, M. ;

Garcia-Monzon, C. ;

Mayo, R. ;

Martin-Duce, A. ;

Romero-Gomez, M. ;

Lo Iacono, O. ;

Tordjman, J. ;

Andrade, R. J. ;

Perez-Carreras, M. ;

Le Marchand-Brustel, Y. ;

Tian, A. ;

Fernandez-Escalante, C. ;

Arevalo, E. ;

Garcia-Unzueta, M. ;

Clement, K. ;

Crespo, J. ;

Gual, P. ;

Gomez-Fleitas, M. ;

Martinez-Chantar, M. L. ;

Castro, A. ;

Lu, S. C. ;

Vazquez-Chantada, M. ;

Mato, J. M. .

JOURNAL OF PROTEOME RESEARCH, 2012, 11 (04) :2521-2532

[2] Personalized Cardiovascular Disease Prediction and Treatment-A Review of Existing Strategies and Novel Systems Medicine Tools [J].

Bjornson, Elias ;

Boren, Jan ;

Mardinoglu, Adil .

FRONTIERS IN PHYSIOLOGY, 2016, 7

[3] Use of a metabolomic approach to non-invasively diagnose non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus [J].

Bril, Fernando ;

Millan, Laura ;

Kalavalapalli, Srilaxmi ;

McPhaul, Michael J. ;

Caulfield, Michael P. ;

Martinez-Arranz, Ibon ;

Alonso, Cristina ;

Betes, Pablo Ortiz ;

Mato, Jose M. ;

Cusi, Kenneth .

DIABETES OBESITY & METABOLISM, 2018, 20 (07) :1702-1709

[4] NAFLD: Reporting Histologic Findings in Clinical Practice [J].

Brunt, Elizabeth M. ;

Kleiner, David E. ;

Carpenter, Danielle H. ;

Rinella, Mary ;

Harrison, Stephen A. ;

Loomba, Rohit ;

Younossi, Zobair ;

Neuschwander-Tetri, Brent A. ;

Sanyal, Arun J. .

HEPATOLOGY, 2021, 73 (05) :2028-2038

[5] Plasma eicosanoids as noninvasive biomarkers of liver fibrosis in patients with nonalcoholic steatohepatitis [J].

Caussy, Cyrielle ;

Chuang, Jen-Chieh ;

Billin, Andrew ;

Hu, Tao ;

Wang, Ya ;

Subramanian, G. Mani ;

Djedjos, C. Stephen ;

Myers, Robert P. ;

Dennis, Edward A. ;

Loomba, Rohit .

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2020, 13

[6] Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease [J].

Caussy, Cyrielle ;

Ajmera, Veeral H. ;

Puri, Puneet ;

Hsu, Cynthia Li-Shin ;

Bassirian, Shirin ;

Mgdsyan, Mania ;

Singh, Seema ;

Faulkner, Claire ;

Valasek, Mark A. ;

Rizo, Emily ;

Richards, Lisa ;

Brenner, David A. ;

Sirlin, Claude B. ;

Sanyal, Arun J. ;

Loomba, Rohit .

GUT, 2019, 68 (10) :1884-1892

[7] Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD [J].

Caussy, Cyrielle ;

Hsu, Cynthia ;

Singh, Seema ;

Bassirian, Shirin ;

Kolar, James ;

Faulkner, Claire ;

Sinha, Nikhil ;

Bettencourt, Ricki ;

Gara, Naveen ;

Valasek, Mark A. ;

Schnabl, Bernd ;

Richards, Lisa ;

Brenner, David A. ;

Hofmann, Alan F. ;

Loomba, Rohit .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 49 (02) :183-193

[8] The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases [J].

Chalasani, Naga ;

Younossi, Zobair ;

Lavine, Joel E. ;

Charlton, Michael ;

Cusi, Kenneth ;

Rinella, Mary ;

Harrison, Stephen A. ;

Brunt, Elizabeth M. ;

Sanyal, Arun J. .

HEPATOLOGY, 2018, 67 (01) :328-357

[9] Increased Risk of Mortality by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis [J].

Dulai, Parambir S. ;

Singh, Siddharth ;

Patel, Janki ;

Soni, Meera ;

Prokop, Larry J. ;

Younossi, Zobair ;

Sebastiani, Giada ;

Ekstedt, Mattias ;

Hagstrom, Hannes ;

Nasr, Patrik ;

Stal, Per ;

Wong, Vincent Wai-Sun ;

Kechagias, Stergios ;

Hultcrantz, Rolf ;

Loomba, Rohit .

HEPATOLOGY, 2017, 65 (05) :1557-1565

[10] Metabolic Phenotyping and Systems Biology Approaches to Understanding Metabolic Syndrome and Fatty Liver Disease [J].

Dumas, Marc-Emmanuel ;

Kinross, James ;

Nicholson, Jeremy K. .

GASTROENTEROLOGY, 2014, 146 (01) :46-62

← 1 2 3 4 →